<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03110861</url>
  </required_header>
  <id_info>
    <org_study_id>TPV-101</org_study_id>
    <nct_id>NCT03110861</nct_id>
  </id_info>
  <brief_title>Pulsta® Transcatheter Pulmonary Valve Korean Multicenter Study</brief_title>
  <official_title>A Prospective, Multicenter, Single Arm Study to Evaluate the Safety and Effectiveness of Implantation of 'Transcatheter Pulmonary Valve (TPV)' for the Treatment of Congenital Heart Disease With Pulmonary Valve Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Taewoong Medical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Taewoong Medical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and effectiveness of the TPV in patients
      with pulmonary valve dysfunction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The TPV is indicated for use in patients with previous undergone replacement of bioprosthetic
      valve or conduit due to either pulmonary valve atresia, stenosis, regurgitation or a
      combination of them and present with dysfunctional right ventricular ourflow tract (RVOT)
      requiring treatment for severe pulmonary regurgitation and/or RVOT conduit obstruction.
      Consecutive subject data should be collected at discharge, 1, 3, 6 month, and 1-5 years post
      TPV implantation.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 22, 2017</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Actual">November 6, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemodynamic functional improvement at 6month</measure>
    <time_frame>6 months</time_frame>
    <description>Hemodynamic functional improvement is defined as mean RVOT gradient ≤30 mmHg by continuous wave doppler, and a pulmonary regurgitant fraction &lt;20% by cardiac magnetic resonance (MR).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Procedural / Device related serious adverse events at 6month</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedural success</measure>
    <time_frame>5 days</time_frame>
    <description>Procedural success is defined as the TPV implant within desired position, Right ventricle-Pulmonary artery (RV-PA) peak systolic pressure gradient &lt;35mmHg by catheter, less mild pulmonary regurgitation by angiography, and freedom from explantation of the TPV at 24 hours post-implant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic function</measure>
    <time_frame>5 years</time_frame>
    <description>Hemodynamic function will be measured including peak RVOT pressure gradient, mean RVOT pressure gradient, RV-PA pressure gradient, RV pressure, cardiac output, cardiac index, RV end-diastolic volume by echocardiography, cardiac MR, or catheterization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of pulmonary regurgitation</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New York Heart Association (NYHA) functional classification</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent fracture</measure>
    <time_frame>5 years</time_frame>
    <description>Stent fracture will be assessed by the investigator through radiography (X-ray, Fluoroscopy).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Catheter reintervention on TPV</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reoperation</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural / Device related serious adverse events</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death (all cause / procedural / device-related)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other adverse events</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary regurgitant fraction</measure>
    <time_frame>6 months</time_frame>
    <description>Pulmonary regurgitant fraction will be measured by cardiac MRI.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Congenital Heart Defect</condition>
  <condition>Pulmonary Valve; Insufficiency, Congenital</condition>
  <condition>Pulmonary Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>Pulsta® Transcatheter Pulmonary Valve</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pulsta® Transcatheter Pulmonary Valve (TaeWoong Medical Co., Ltd. Korea)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pulsta® Transcatheter Pulmonary Valve (TPV) Replacement</intervention_name>
    <description>Pulsta® Transcatheter Pulmonary Valve Replacement</description>
    <arm_group_label>Pulsta® Transcatheter Pulmonary Valve</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body weight greater than or equal to 30 kilograms

          -  Pulmonary regurgitation ≥moderate pulmonary regurgitation (PR) (≥3+) or RVOT conduit
             obstruction with mean gradient &gt;35mmHg by echocardiography

          -  pulmonary artery annulus or in situ conduit size of ≥16 and ≤26mm

          -  Patient willing to provide written informed consent and comply with follow-up
             requirements

        Exclusion Criteria:

          -  Pre-existing mechanical heart valve in any position

          -  Obstruction of the central veins (pulmonic bioprosthesis delivery system to the heart)

          -  Coronary artery compression

          -  A known hypersensitivity to Aspirin or Heparin

          -  Immunosuppressive disease

          -  Active infectious disease (e.g. endocarditis, meningitis)

          -  Estimated survival less than 6 months

          -  Female of child-bearing potential who are unable to take adequate contraceptive
             precautions, are known to be pregnant, or are currently breastfeeding an infant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gi Beom Kim, phD. MD.</last_name>
    <role>Study Chair</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Haehak-ro Jongno-gu</state>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sejong General Hospital</name>
      <address>
        <city>Bucheon</city>
        <state>Hohyun-ro, Sosa-gu</state>
        <zip>14754</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Ilwon-ro, Gangnam-gu</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Olympic-ro, Songpa-gu</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Yonsei-ro, Seodaemun-gu</state>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>April 7, 2017</study_first_submitted>
  <study_first_submitted_qc>April 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2017</study_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
    <mesh_term>Pulmonary Valve Stenosis</mesh_term>
    <mesh_term>Pulmonary Valve Insufficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

